Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 3/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24424515 | 0.75 | ADH1B (0.38) | — | |
| SCHEMBL23623038 | 0.69 | IDO1 (0.33) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL24928597 | 0.69 | CYP19A1 (0.35) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL15729508 | 0.66 | HTR5A (0.44) | NCF1AKT2ROCK2ROCK1CDC42BPB | |
| SCHEMBL20225483 | 0.65 | MAPT (0.32) | — | |
| SCHEMBL24311863 | 0.64 | CYP11B1 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL24928605 | 0.61 | — | — | |
| SCHEMBL23729877 | 0.61 | — | — | |
| Hydrochloric Acid SCHEMBL25303729 | 0.59 | CYP17A1 (0.37) | — | |
| SCHEMBL368186 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | NCF1 1702/4885AKT2 1265/4885ROCK2 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.